Compare HCAT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | ATYR |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 79.2M |
| IPO Year | 2019 | 2015 |
| Metric | HCAT | ATYR |
|---|---|---|
| Price | $2.38 | $0.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $4.30 | ★ $8.75 |
| AVG Volume (30 Days) | 666.8K | ★ 2.0M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $316,063,000.00 | $190,000.00 |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.63 | N/A |
| 52 Week Low | $2.02 | $0.64 |
| 52 Week High | $7.65 | $7.29 |
| Indicator | HCAT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 43.06 |
| Support Level | $2.32 | $0.69 |
| Resistance Level | $2.49 | $0.76 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 15.58 | 29.82 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.